How Dr. Daniel Drucker’s GLP-1 research is reshaping treatments beyond weight loss
Dr. Daniel Drucker’s lab at Mount Sinai is mapping how GLP-1 drugs like semaglutide protect liver, heart and kidneys independent of weight loss.
Copy link
By Torontoer Staff
Dr. Daniel Drucker, the endocrinologist whose work helped turn a peptide from Gila monster venom into medicines such as Ozempic and Wegovy, is continuing to map how GLP-1 receptor agonists do more than lower blood sugar and trim weight. His team at Mount Sinai’s Lunenfeld-Tanenbaum Research Institute is producing experiments that suggest these drugs can directly protect the liver, reduce chronic inflammation and lower risks for heart, kidney and other diseases.
Those findings could change how clinicians use GLP-1s, and how drugmakers design the next generation of treatments. The lab’s work points to mechanisms that act independently of appetite suppression and weight loss, so some benefits may appear even when patients do not lose much weight.
From Gila monster venom to modern GLP-1 medicines
In the mid-1990s, Dr. Drucker analysed a peptide from Gila monster venom, later named exendin-4, and showed it acted on GLP-1 receptors while resisting rapid degradation. His 1997 paper helped establish a biochemical path that led to short-acting GLP-1 drugs for diabetes and the longer-acting semaglutide that underpins today’s widely prescribed products.
Dr. Drucker keeps a tangible reminder of that work in his lab, and he acknowledges the unusual origin of these medicines without turning aside from the science. The discovery set a foundation for labs worldwide to probe where GLP-1 receptors sit in the body and how agonists exert effects beyond the pancreas and hypothalamus.
Lab findings: benefits that do not require weight loss
One recurring result from Dr. Drucker’s team is that semaglutide can improve organ health even when weight remains stable. In controlled mouse experiments the lab ensured treated animals did not lose weight, and still observed improvements in liver tests and tissue structure.
We can do experiments where we can make sure that the mice we’re treating have no weight loss, they’re getting the GLP-1 medicine and they still have these tremendous benefits in improving liver health, despite the fact that they’re losing no weight.
Dr. Daniel Drucker
Research by Maria Jesus Gonzalez-Rellan illustrates how those weight-loss independent effects can be localized. She compared obese wild-type mice with animals engineered to lack GLP-1 receptors in the brain. Both groups received semaglutide or saline, and while only the wild-type mice lost weight, liver function improved in both groups.
Both weight-loss dependent mechanisms and weight-loss independent mechanisms are important for liver health, and this was a surprise.
Dr. Maria Jesus Gonzalez-Rellan
Delving deeper, the team found GLP-1 receptors on specialised endothelial cells in the liver’s small blood vessels. When those cells were engineered to lack receptors, semaglutide still produced weight loss but many of the liver benefits disappeared. The finding suggests that improved liver outcomes result from multiple pathways, not weight loss alone.
Inflammation, the brain and immune-cell targets
Other lab members are tracing how GLP-1s modulate inflammation. Postdoctoral scientist Chi Kin Wong published studies showing semaglutide acts on immune cells in the gut, and later that brain GLP-1 receptors can dampen systemic inflammation even where receptors are scarce on immune cells themselves.
We found that there’s a population of immune cells in the gut that the drug can directly act on and reduce inflammation there.
Dr. Chi Kin Wong
Those short-term experiments produced anti-inflammatory effects before weight loss could explain them, which is one reason researchers are testing GLP-1s in inflammatory conditions such as rheumatoid arthritis. At the same time, the lab is studying how the related gut hormone GIP contributes to outcomes when combined with GLP-1 in drugs such as tirzepatide.
Weight loss and appetite control is not simply a will-power problem, but it is actually a more complex physiological process.
Dr. Rola Hammoud
Conditions GLP-1s are being linked to
- Type 2 diabetes, blood-glucose regulation
- Obesity and weight management
- Liver disease, including metabolic dysfunction–associated steatohepatitis
- Chronic inflammation and potential inflammatory diseases
- Cardiovascular risk reduction, including heart attacks and strokes
- Kidney disease and improved renal markers
- Possible benefits for sleep apnea and joint disease under study
What the research means for patients and drug development
The lab’s discoveries are practical, not merely theoretical. Identifying which cells and tissues respond directly to GLP-1 helps researchers design molecules that target specific pathways, and may explain why early hopes for neurodegenerative disease benefits have not always panned out. The work also has implications for regulatory decisions; Health Canada gave conditional approval for semaglutide in metabolic dysfunction–associated steatohepatitis late last year.
Dr. Drucker’s lab has received industry funding over the years, which the team discloses while pursuing independent mechanistic science. Those mechanistic insights could inform future drugs that preserve advantages seen with current GLP-1s while improving safety or efficacy for particular conditions.
What to watch next
Expect more papers from the Mount Sinai group on how GLP-1 receptor location and cell type shape clinical outcomes. Trials that separate weight-loss effects from other mechanisms will be important for clinicians deciding when and how to prescribe these medicines, and for patients weighing benefits beyond pounds lost.
For now, Dr. Drucker and his colleagues are pursuing questions that could expand therapeutic uses for GLP-1 agonists and refine how they are deployed. Their work suggests the drugs’ impact is broader than appetite suppression alone, and that understanding those mechanisms will drive the next wave of treatments.
GLP-1OzempicsemaglutidehealthresearchMount Sinaidiabetesliver disease
